{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:08:32Z","timestamp":1782166112511,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA222490"],"award-info":[{"award-number":["R01CA222490"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA243787"],"award-info":[{"award-number":["R50CA243787"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020490","name":"UC Davis Health","doi-asserted-by":"publisher","award":["UCDCCC seed grant"],"award-info":[{"award-number":["UCDCCC seed grant"]}],"id":[{"id":"10.13039\/100020490","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biosci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment options for hepatocellular carcinoma (HCC) are limited, and there is no effective drug that can improve long-term survival rates. Complicated cocktails consisting of multiple medications with toxicities are frequently used to treat cancer. The current study addresses these challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study uses metabolic dysfunction-associated steatohepatitis (MASH)-HCC and HCC mouse models established by transfecting the livers using myr-AKT1, NRasV12, and Sleeping Beauty transposase. AAV8-miR-22 was delivered to MASH-HCC and HCC to study its preventive and therapeutic effects. Spatial transcriptomic profiling revealed the signaling pathways affected by miR-22 according to histological locations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>miR-22 treatment effectively treated MASH-HCC and HCC. Treating mice with miR-22 before tumor initiation prevented oncogenesis. The promising anti-cancer effects were revealed by reduced tumor load, fibrosis, and splenomegaly, extending the survival time. miR-22 treatment generated anti-tumor immunity. The favorable treatment outcomes were accompanied by a reduction in dendritic cells, T and B cells, and plasma cells, which were expanded inside the tumors of MASH-HCC. In all animal trials, miR-22 improved metabolism and reduced glycolysis inside the tumors. Moreover, miR-22 profoundly inhibited extracellular matrix (ECM) and targeted MET, PDGF, tyrosine kinase signaling, and IGF pathways inside the tumors. Furthermore, the roles of miR-22 in blocking collagen formation and cross-assembly of collagen fibrils could be due to miR-22's effects in inhibiting Rho GTPase pathways, revealed at the tumor margin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>miR-22 generates anti-HCC effects by targeting many critical pathways in liver carcinogenesis in cancer and tumorigenic niches, potentially revolutionizing HCC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13578-025-01352-7","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T13:35:29Z","timestamp":1739540129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multi-pathway targeted therapy of MASH-HCC using miR-22"],"prefix":"10.1186","volume":"15","author":[{"given":"Ying","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Setayesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongguang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trenton","family":"Testerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2243-7759","authenticated-orcid":false,"given":"Yu-Jui Yvonne","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"10","key":"1352_CR1","doi-asserted-by":"publisher","first-page":"6507","DOI":"10.1074\/jbc.M114.620369","volume":"290","author":"F Yang","year":"2015","unstructured":"Yang F, Hu Y, Liu HX, Wan YJ. MiR-22-silenced cyclin a expression in colon and liver cancer cells is regulated by bile acid receptor. J Biol Chem. 2015;290(10):6507\u201315.","journal-title":"J Biol Chem"},{"issue":"2","key":"1352_CR2","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1096\/fj.201801390R","volume":"33","author":"Y Hu","year":"2019","unstructured":"Hu Y, French SW, Chau T, Liu HX, Sheng L, Wei F, Stondell J, Garcia JC, Du Y, Bowlus CL, et al. RARbeta acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells. FASEB J. 2019;33(2):2314\u201326.","journal-title":"FASEB J"},{"issue":"10","key":"1352_CR3","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1093\/hmg\/dds031","volume":"21","author":"S Alvarez-Diaz","year":"2012","unstructured":"Alvarez-Diaz S, Valle N, Ferrer-Mayorga G, Lombardia L, Herrera M, Dominguez O, Segura MF, Bonilla F, Hernando E, Munoz A. MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet. 2012;21(10):2157\u201365.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"1352_CR4","first-page":"4932","volume":"8","author":"J Chen","year":"2016","unstructured":"Chen J, Wu FX, Luo HL, Liu JJ, Luo T, Bai T, Li LQ, Fan XH. Berberine upregulates miR-22-3p to suppress hepatocellular carcinoma cell proliferation by targeting Sp1. Am J Transl Res. 2016;8(11):4932\u201341.","journal-title":"Am J Transl Res"},{"issue":"49","key":"1352_CR5","doi-asserted-by":"publisher","first-page":"80751","DOI":"10.18632\/oncotarget.13037","volume":"7","author":"M Chen","year":"2016","unstructured":"Chen M, Hu W, Xiong CL, Qu Z, Yin CQ, Wang YH, Luo CL, Guan Q, Yuan CH, Wang FB. miR-22 targets YWHAZ to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival. Oncotarget. 2016;7(49):80751\u201364.","journal-title":"Oncotarget"},{"key":"1352_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12935-016-0380-8","volume":"17","author":"LJ Luo","year":"2017","unstructured":"Luo LJ, Zhang LP, Duan CY, Wang B, He NN, Abulimiti P, Lin Y. The inhibition role of miR-22 in hepatocellular carcinoma cell migration and invasion via targeting CD147. Cancer Cell Int. 2017;17:17.","journal-title":"Cancer Cell Int"},{"issue":"35","key":"1352_CR7","doi-asserted-by":"publisher","first-page":"57099","DOI":"10.18632\/oncotarget.10981","volume":"7","author":"Y You","year":"2016","unstructured":"You Y, Tan JX, Dai HS, Chen HW, Xu XJ, Yang AG, Zhang YJ, Bai LH, Bie P. MiRNA-22 inhibits oncogene galectin-1 in hepatocellular carcinoma. Oncotarget. 2016;7(35):57099\u2013116.","journal-title":"Oncotarget"},{"issue":"2","key":"1352_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100093","volume":"2","author":"Y Hu","year":"2020","unstructured":"Hu Y, Liu HX, Jena PK, Sheng L, Ali MR, Wan YY. miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction. JHEP Rep. 2020;2(2): 100093.","journal-title":"JHEP Rep"},{"issue":"6","key":"1352_CR9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ymthe.2023.04.019","volume":"31","author":"Y Hu","year":"2023","unstructured":"Hu Y, Setayesh T, Vaziri F, Wu X, Hwang ST, Chen X, Yvonne Wan YJ. miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism. Mol Ther. 2023;31(6):1829\u201345.","journal-title":"Mol Ther"},{"issue":"18","key":"1352_CR10","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.3390\/cells11182860","volume":"11","author":"M Gjorgjieva","year":"2022","unstructured":"Gjorgjieva M, Ay AS, Correia de Sousa M, Delangre E, Dolicka D, Sobolewski C, Maeder C, Fournier M, Sempoux C, Foti M. MiR-22 deficiency fosters hepatocellular carcinoma development in fatty liver. Cells. 2022;11(18):2860.","journal-title":"Cells."},{"key":"1352_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000786","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang L, Dong B. Molecular mechanisms in MASLD\/MASH-related HCC. Hepatology. 2024. https:\/\/doi.org\/10.1097\/HEP.0000000000000786.","journal-title":"Hepatology"},{"issue":"1","key":"1352_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s40364-024-00660-3","volume":"12","author":"T Setayesh","year":"2024","unstructured":"Setayesh T, Hu Y, Vaziri F, Wei D, Wan YY. The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model. Biomark Res. 2024;12(1):122.","journal-title":"Biomark Res"},{"issue":"3","key":"1352_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","volume":"79","author":"M Li","year":"2024","unstructured":"Li M, Wang L, Cong L, Wong CC, Zhang X, Chen H, Zeng T, Li B, Jia X, Huo J, et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology. 2024;79(3):560\u201374.","journal-title":"Hepatology"},{"issue":"5","key":"1352_CR14","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1096\/fj.201700984RR","volume":"32","author":"PK Jena","year":"2018","unstructured":"Jena PK, Sheng L, Di Lucente J, Jin LW, Maezawa I, Wan YY. Dysregulated bile acid synthesis and dysbiosis are implicated in Western diet-induced systemic inflammation, microglial activation, and reduced neuroplasticity. FASEB J. 2018;32(5):2866\u201377.","journal-title":"FASEB J"},{"issue":"6","key":"1352_CR15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jid.2018.12.002","volume":"139","author":"S Yu","year":"2019","unstructured":"Yu S, Wu X, Zhou Y, Sheng L, Jena PK, Han D, Wan YJY, Hwang ST. A Western diet, but not a high-fat and low-sugar diet, predisposes mice to enhanced susceptibility to imiquimod-induced psoriasiform dermatitis. J Invest Dermatol. 2019;139(6):1404\u20137.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1352_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41416-020-01172-1","volume":"124","author":"L Boulter","year":"2021","unstructured":"Boulter L, Bullock E, Mabruk Z, Brunton VG. The fibrotic and immune microenvironments as targetable drivers of metastasis. Br J Cancer. 2021;124(1):27\u201336.","journal-title":"Br J Cancer"},{"issue":"7999","key":"1352_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-06991-9","volume":"626","author":"W Fan","year":"2024","unstructured":"Fan W, Adebowale K, Vancza L, Li Y, Rabbi MF, Kunimoto K, Chen D, Mozes G, Chiu DK, Li Y, et al. Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver. Nature. 2024;626(7999):635\u201342.","journal-title":"Nature"},{"issue":"2","key":"1352_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41416-022-01775-w","volume":"127","author":"SM Afify","year":"2022","unstructured":"Afify SM, Hassan G, Seno A, Seno M. Cancer-inducing niche: the force of chronic inflammation. Br J Cancer. 2022;127(2):193\u2013201.","journal-title":"Br J Cancer"},{"key":"1352_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ceb.2018.09.003","volume":"56","author":"H Warner","year":"2019","unstructured":"Warner H, Wilson BJ, Caswell PT. Control of adhesion and protrusion in cell migration by Rho GTPases. Curr Opin Cell Biol. 2019;56:64\u201370.","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"1352_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0092-8674(95)90370-4","volume":"81","author":"CD Nobes","year":"1995","unstructured":"Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell. 1995;81(1):53\u201362.","journal-title":"Cell"},{"key":"1352_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.674426","volume":"11","author":"J Liang","year":"2021","unstructured":"Liang J, Oyang L, Rao S, Han Y, Luo X, Yi P, Lin J, Xia L, Hu J, Tan S, et al. Rac1, A potential target for tumor therapy. Front Oncol. 2021;11: 674426.","journal-title":"Front Oncol"},{"issue":"6","key":"1352_CR22","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.4049\/jimmunol.174.6.3394","volume":"174","author":"GV Shurin","year":"2005","unstructured":"Shurin GV, Tourkova IL, Chatta GS, Schmidt G, Wei S, Djeu JY, Shurin MR. Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol. 2005;174(6):3394\u2013400.","journal-title":"J Immunol"},{"issue":"1","key":"1352_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23\u201336.","journal-title":"Blood"},{"issue":"10","key":"1352_CR24","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1016\/j.ymthe.2024.08.002","volume":"32","author":"MB Demircan","year":"2024","unstructured":"Demircan MB, Zinser LJ, Michels A, Guaza-Lasheras M, John F, Gorol JM, Theuerkauf SA, Gunther DM, Grimm D, Greten FR, et al. T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8. Mol Ther. 2024;32(10):3470\u201384.","journal-title":"Mol Ther"},{"issue":"1","key":"1352_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/hep.24625","volume":"55","author":"M Hosel","year":"2012","unstructured":"Hosel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, Gillen S, Kleeff J, Stabenow D, Odenthal M, et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology. 2012;55(1):287\u201397.","journal-title":"Hepatology"},{"issue":"6","key":"1352_CR26","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16(6):1073\u201380.","journal-title":"Mol Ther"},{"issue":"1","key":"1352_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.apsb.2023.10.010","volume":"14","author":"T Setayesh","year":"2024","unstructured":"Setayesh T, Hu Y, Vaziri F, Chen X, Lai J, Wei D, Yvonne Wan YJ. Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma. Acta Pharm Sin B. 2024;14(1):292\u2013303.","journal-title":"Acta Pharm Sin B"},{"issue":"14","key":"1352_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308242","volume":"11","author":"F Vaziri","year":"2024","unstructured":"Vaziri F, Setayesh T, Hu Y, Ravindran R, Wei D, Wan YY. BCG as an innovative option for HCC treatment: repurposing and mechanistic insights. Adv Sci. 2024;11(14): e2308242.","journal-title":"Adv Sci"},{"issue":"4","key":"1352_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s13402-011-0035-7","volume":"34","author":"AM Hadi","year":"2011","unstructured":"Hadi AM, Mouchaers KT, Schalij I, Grunberg K, Meijer GA, Vonk-Noordegraaf A, van der Laarse WJ, Belien JA. Rapid quantification of myocardial fibrosis: a new macro-based automated analysis. Cell Oncol. 2011;34(4):343\u201354.","journal-title":"Cell Oncol"},{"issue":"3","key":"1352_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/bioinformatics\/btab711","volume":"38","author":"YR Miao","year":"2022","unstructured":"Miao YR, Xia M, Luo M, Luo T, Yang M, Guo AY. ImmuCellAI-mouse: a tool for comprehensive prediction of mouse immune cell abundance and immune microenvironment depiction. Bioinformatics. 2022;38(3):785\u201391.","journal-title":"Bioinformatics"},{"issue":"7","key":"1352_CR31","doi-asserted-by":"publisher","first-page":"1902880","DOI":"10.1002\/advs.201902880","volume":"7","author":"YR Miao","year":"2020","unstructured":"Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, Guo AY. ImmuCellAI: A unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci. 2020;7(7):1902880.","journal-title":"Adv Sci"}],"container-title":["Cell &amp; Bioscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13578-025-01352-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13578-025-01352-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13578-025-01352-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T13:35:32Z","timestamp":1739540132000},"score":1,"resource":{"primary":{"URL":"https:\/\/cellandbioscience.biomedcentral.com\/articles\/10.1186\/s13578-025-01352-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1186\/s13578-025-01352-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5589255\/v1","asserted-by":"object"}]},"ISSN":["2045-3701"],"issn-type":[{"value":"2045-3701","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiment was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, Davis (IACUC No. 23761).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}